Macupatide and Eloralintide for Weight Management
A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
- Age
- 18 – 75
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 400 (estimated)
- Sponsor
- Eli Lilly and Company · Industry
This trial is looking for adults with obesity or overweight who do not have type 2 diabetes. Participants will take either macupatide and eloralintide together or a placebo for about 64 weeks.
You may not be able to join if
- I have type 1 diabetes or type 2 diabetes
- I have an ongoing history of bradyarrhythmia and/or sinus bradycardia
- I have an elevated resting pulse rate (greater than 100 bpm) or reduced resting pulse rate (less than 60 bpm)
- I have a history of acute or chronic pancreatitis
- All my medications have not been at a stable dose for at least 3 months prior to screening
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your EligibilityThe main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to examine the body weight-lowering efficacy and safety of macupatide plus eloralintide compared with placebo in participants with obesity or overweight and without type 2 diabetes. Participation will last about 64 weeks.
Loading trial locations…
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
317-615-4559
CONTACT
Physicians interested in becoming principal investigators please contact
clinical_inquiry_hub@lilly.com
CONTACT